logo
Sinus Headache … Or Is It?

Sinus Headache … Or Is It?

WebMD2 days ago

For many years, I thought I had all the headaches of the rainbow. Migraine? Yes. Tension? Absolutely. Sinus? Without fail. Add in the headaches you get during a major bout with a cold, flu, or COVID, and I pretty much thought I had a degree in headaches.
My medicine cabinet also represented the many treatments for any type of headache on any given day. I often smiled, knowing I would have something to barter in the apocalypse. I'd be the medicine woman trading Tylenol PMs for bread!
Now let's be clear, I've been that chick!
From an early age, I was the one who (when I was old enough to do so) had headache medication for anyone who needed it. I felt valuable being able to help someone escape a pain that I was all too familiar with.
This system has made me a little scattered when planning, especially for travel. I've had to make sure I have my prescription migraine medication, some type of painkiller for a 'regular' headache, some sinus headache medication if we're talking March through early June, and then again in late September through early November. Right when the fall allergy season ends, I'm armed with headache medication for the cold and flu season.
I'll also improvise when I need to. In the past, if I'd been caught off guard with what I believed to be a sinus headache, I'd take a Tylenol and then some generic sinus medication or do a neti pot. The goal was to attack it from the side if I couldn't attack it head-on.
But as things commonly go with me and migraine, I learned something new recently that blew my mind.
I was speaking to a neurologist about migraine (shout-out to Dr. Paul Mathew), and he said, 'You know, many people will think they're having a sinus or tension headache when it's actually a migraine.'
Wait, what?!
You mean all of these years, I've been walking around with an entire drugstore in my purse for no reason? But being a natural skeptic, I had to look it up myself. Sure enough, studies show that 90% of self-diagnosed sinus headaches are migraine attacks. I hate to be known as someone who follows the crowd, but dang it, I've been living in that 90%!
For years, I wondered why traditional sinus medications would do nothing for my sinus headaches. I'd up the dose, I'd switch brands. I'd take a steam shower. I'd do all the things! Still, my 'sinus' headache would hang around for days. I'd be miserable. I'd call out of work sometimes. I'd be bedridden for days sometimes. I hated the spring. All along, I was dealing with a migraine.
Honestly, I should have known. I mean, I had the classic migraine symptoms – sensitivity to light, nausea … oh, the nausea! I used to walk around God's green earth telling other people that my sinus headaches felt 'a lot like a migraine.' It's almost funny now. Almost.
Beyond sounding very headache illiterate, the worst part of it all was that I was delaying my treatment. I was suffering for days sometimes, never once glancing at my migraine medication.
But if you've been confused like me about how sinus and migraine headaches are different, don't feel bad. It seems they can have similar symptoms and triggers.
Changes in weather and seasons can trigger both migraine attacks and sinus headaches.
Both can have pain behind the eyes.
Both can have a runny nose and watery eyes.
It's no wonder most of us get it wrong when it comes to these types of headaches. The same nerves are involved in the face, mouth, jaw, head, and sinuses. But I've been reading that sinus headaches are pretty rare.
We're nose-deep in allergy season where I live. Thankfully, I'm not in a place where yellow pollen covers the cars anymore, but the dry (sometimes dusty) air can kick up all kinds of allergens. All I know is I used to hate the spring and all its flowery-ness. I would gear up for days – sometimes weeks – of what I now know are migraine attacks.
But as the old folks say: 'When you know better, you do better.' Now, when I feel a migraine attack coming on, I will treat it as such … and quickly! After all, there are roses to smell and long days to enjoy.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kennedy names 8 vaccine committee replacements, including COVID shot critic
Kennedy names 8 vaccine committee replacements, including COVID shot critic

Associated Press

time29 minutes ago

  • Associated Press

Kennedy names 8 vaccine committee replacements, including COVID shot critic

NEW YORK (AP) — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. They include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. Kennedy's decision to 'retire' the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Kennedy made the announcement in a social media post on Wednesday. The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. ___ Associated Press reporter Amanda Seitz contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Taletrectinib Approved for NSCLC
Taletrectinib Approved for NSCLC

Medscape

timean hour ago

  • Medscape

Taletrectinib Approved for NSCLC

The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store